Novel oral anticoagulant prescriptions soar, but at a high cost
Warfarin, the longtime standard treatment for atrial fibrillation, is facing competition from new options in the anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. A new study documents the rapid ...
Aug 19, 2014
0
0